Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Dermatology
  • Dermatology Guidelines
  • Amphotericin-B in...

Amphotericin-B in dermatology-a review

Written By : Dr Manoj Kumar Nayak |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-11-14T20:00:21+05:30  |  Updated On 15 Nov 2022 12:32 PM IST
Amphotericin-B in dermatology-a review
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Amphotericin B (AmB) is one of the most potent antifungal drugs against invasive fungal infections which has stood the test of time. AmB deoxycholate (d‑AmB) was first preparation of AmB, marketed in 1959. The COVID19 pandemic had again highlighted its role with the rise in cases of mucormycosis. Recently a review reappraising the drug profile of AmB and its use in the field of dermatology was published in the Indian Dermatology Online Journal.

AmB is a macrolide polyene antifungal, obtained from soil actinomycete Streptomyces nodosus via the process of fermentation. As AmB is amphoteric and water‑insoluble, only parenteral formulations are available. Due to the infusion‑related reactions and nephrotoxicity of the drug, lipid‑based formulations were prepared such as liposomal AmB (l‑AmB), AmB lipid complex (ABLC), and AmB colloidal dispersion (ABCD). Recently, various topical formulations of AmB have been successfully used in cutaneous leishmaniasis and mucormycosis. The salient points related to the four formulations of AmB have been summarized in the table-1 below.

Mechanism of Action

AmB acts via selective binding to ergosterol, a key component of the fungal cell membrane, leading to the formation of pores on the cell membrane. Pore formation results in K+ efflux, fungal glycolysis inhibition, and Mg++ efflux with simultaneous proton influx. The increased acidification of fungal cytoplasm results in the precipitation of proteins and subsequent cell death. Additional mechanisms proposed include oxidative damage via free radical formation and stimulation of the phagocytic system to aid fungal clearance.

FDA Approved Indications of Liposomal AmB -

1. Empirical therapy for presumed fungal infection in febrile, neutropenic patients.

2. Cryptococcal meningitis in HIV infected patients

3. Patients with Aspergillus species, Cryptococcus species, or Candida species infection refractory to amphotericin B deoxycholate, or patients with renal impairment or prior hypersensitivity to amphotericin B deoxycholate.

4. Treatment of visceral leishmaniasis.

Dermatological Uses of AmB

Leishmaniasis

The action of AmB in leishmaniasis is attributed to its selective affinity to bind to ergosterol present in the parasite's cell membrane. Other mechanisms postulated include cell membrane disruption by lipid peroxidation, endosome‑lysosome fusion inhibition, apoptosis, and stimulation of INF‑Y production resulting in macrophage activation.

Mucocutaneous leishmaniasis:

i. Systemic therapy

AmB and miltefosine are the preferred drug of choice. L‑AmB is the standard formulation preferred. Recommended WHO dosing is 2–3 mg/kg per day, by infusion, up to 40–60 mg/kg total dose. Immunocompromised patients often need higher and prolonged therapy. The treatment regime comprises 3 mg/kg L‑AMB for 5 consecutive days followed by the 6th dose on day 10.

ii. Topical therapy:

The first successful use described was in 1999 using AmB in 5% ethanol. The aim of topical formulation was to prevent systemic toxicity. As of now, studies regarding topical AmB are not encouraging for cutaneous leishmaniasis. However, various other formulations of topical AmB such as liposomal, nanoparticles, ultra‑deformable liposomes, and micro needling–based delivery are under trials.

iii. Intralesional therapy:

The first use of intralesional AmB was by Vahid et al where 2 mg/mL was injected into lesions

weekly for up to 12 weeks with 61.4% of the patients showing complete recovery.(2) A comparative trial has shown AmB 2.5 mg/mL to be equally efficacious as 5 mg/mL.(3)

Post kala azar dermal leishmaniasis:

L‑AmB is the second‑line treatment of post kala azar dermal leishmaniasis in patients where miltefosine is contraindicated. Combination therapy of L‑AmB and miltefosine has been shown to be superior in efficacy and safety in patients with PKDL.

Recommended dosing:

i. Africa: L‑AmB: 2.5 mg/kg per day by infusion for 20 days

ii. Asian countries: D‑AmB: 1 mg/kg per day by infusion, up to 60–80 doses over 4 months.

L‑AmB: 30 mg/kg in 6 weekly divided doses of 5 mg/kg

Cutaneous mucormycosis

Systemic therapy

It is caused by opportunistic fungi of class Glomerulomycota via penetrative trauma, commonly affecting patients with immunosuppression and uncontrolled diabetes. Treatment of choice is AMB along with surgical debridement and control of underlying immunosuppression. Treatment is to be started within 5 days of diagnosis. Recommended duration is up to clinical or radiological resolution or at least 6–8 weeks of therapy. Successful use of L‑AmB in cutaneous mucormycosis in preterm neonates and infants has also been described.

Recommended dosing:

i. D‑AMB: 0.5–1 mg/kg/day in immunocompetent and 1–1.5 mg/kg/day in immunosuppressed individuals.

ii. L‑AmB: 5–10 mg/kg/day.

Congenital candidiasis and neonatal candidiasis:

Systemic therapy:

Systemic therapy with AMB is recommended in neonates with widespread dermatitis due to Candida, disseminated invasive disease, respiratory distress in the immediate neonatal period and/or sepsis. AmB at the dosage of 0.5–1 mg/kg/day is preferred, whereas L‑AmB (35 mg/kg/day) is reserved for invasive cases or patients with renal insufficiency. Systemic therapy

is continued for a duration of 21–28 days. The infectious disease society of America recommends the use of amphotericin B deoxycholate oral suspension as an alternative for fluconazole‑refractory oral candidiasis.

Topical therapy:

Topical formulation of AmB has been used for the treatment of oral candidiasis, but the availability of such formulations is a major limiting factor.

Other indications:

• Anecdotal case reports of successful use of AmB have been described in cutaneous fusariosis, protothecosis, primary cutaneous aspergilloisis, cutaneous histoplasmosis, chromoblastomycosis and blastomycosis.

Contraindications

AmB is contraindicated in those patients with known hypersensitivity to it or one of the preservatives.

Storage and Administration

To be stored in dry form at 2–8°C away from light. The salient points to remember during infusion and monitoring of AmB have been summarized as follows-

Intravenous infusion of AmB

Test dose: A test dose of 0.1 mg/kg, and total not exceeding 1 mg is given by infusion over 20-60 min. Infusion after test dose is given over 2-6 h usually via a distal vein. Pre‑treatment with acetaminophen, diphenhydramine, or corticosteroids administered approximately 30 min before infusion can be done in patients developing infusion‑related toxicities. Proper hydration and potassium supplementation are important.

Monitoring during AmB therapy

 Infusion‑related toxicities : like nausea, vomiting, and chills occurring either immediately or within 15 min-3 h of infusion.

 Nephrotoxicity- daily monitoring of serum creatinine is recommended.

 Consider switching to liposomal AmB in case serum creatinine rises over 2.5 mg/dL or reduction of the dose of d‑AmB by 50%.

 Hypokalemia, hypomagnesemia, hypocalcemia, and hypophosphatemia are noted with AmB therapy.

 Potassium and magnesium supplementation along with hydration with normal saline is essential during amphotericin B infusions.

D‑AmB: A total of 50 mg vial is reconstituted with 10 mL sterile water (5 mg/mL) and shaken till the solution becomes clear. This is further diluted to 0.1 mg/mL with 500 mL 5% dextrose and then administered immediately. L‑AmB: A total of 50 mg is reconstituted with 12 mL sterile water (4 mg/mL) and shaken to obtain clear fluid. Further dilution with an appropriate amount of reconstituted solution and 5% dextrose can be done to provide 1–2 mg/mL concentration for adults and 0.2–0.5 mg/mL concentration for infants and small children.

Drug Interactions

Dose‑dependant nephrotoxicity and infusion‑related electrolyte imbalance can be augmented by ongoing concomitant medication. Tacrolimus or cyclosporine used in kidney transplant patients increases AMB‑related toxicity. Increased risk of hypokalemia occurs with the concomitant use of digoxin and corticosteroids.

AmB in Paediatric Population

The safety and effectiveness of AmB in pediatric leishmaniasis have been well documented in the literature. D‑AmB is more hepatotoxic than L‑AmB with no difference in infusion‑related toxicities or nephrotoxicity. Recommended dosing is similar to adults. (3–5 mg/kg/day for 5 days and then another dose on day 10).

AmB in Pregnancy and Lactation

Pregnancy: AmB is a category B drug and thus can be used if clinically indicated. It is the safest antifungal drug during pregnancy with established safety and efficacy of both liposomal and d‑AmB.

Lactation: Whether AmB gets secreted in breast milk is not known, but because it is highly protein‑bound, has a large molecular weight, and is not absorbed orally, it can be used in nursing mothers but with caution.

AmB in Special Population

No dose adjustment is necessary for patients with renal impairment based on CrCl estimate. Liposomal AmB has been successfully administered in patients with pre‑existing renal impairment. Effect of liposomal AmB in patients with hepatic impairment is not known

AmB Resistance

Fortunately, resistance to AmB is still rare compared to other anti‑fungal drugs. Two possible theories have been put forward- One is that AmB targets a major cell membrane component, ergosterol unlike other antifungals which target an enzyme. Another theory proposed is an association of AmB with severe fitness trade‑offs. Resistance that is MIC>2 mg/L is mostly species‑specific and has emerged slowly with some clinical isolates with AmB. Studies on drug combination in vitro and in vivo have suggested that imidazoles can induce AmB resistance.

The following methods of AmB resistance have been suggested:

1. Alterations in sterol composition in the fungal cell membrane. It involves mutations in genes

related biosynthesis pathway. Similar mutations in Candida species being a mechanism of resistance have been reported.

2. Reduction in polyene‑induced oxidative stress may allow better tolerability to AmB. Intrinsically, AmB resistant organisms such as Aspergillus tereus have shown this mechanism of resistance.

3. Alteration in the fungal cell wall has also shown AmB resistance. An increase in the 1, 3 α‑glucan fraction and 1,3‑β‑glucan in Aspergillus flavus and Candida tropicalis, respectively have been postulated to cause resistance.

Source

1. Agarwal A, Kar BR. Amphotericin-B in dermatology. Indian Dermatol Online J 2022;13:152-8.

2. Vahid MG, Elham V, Bita K, Yalda N. Efficacy of intralesional amphotericin B in cutaneous leishmaniasis. Indian J Dermatol 2014;59:631.

3. Goswami P, Ghiya BC, Kumar V, Rekha S, Mehta RD. Comparison of efficacy of two different concentrations of intralesional amphotericin B in the treatment of cutaneous leishmaniasis; A randomized controlled trial. Indian Dermatol Online J 2019;10:627-31.

4. Ramesh V, Dixit KK, Sharma N, Singh R, Salotra P. Assessing the Efficacy and Safety of liposomal amphotericin B and miltefosine in combination for treatment of post Kala-Azar dermal leishmaniasis. J Infect Dis 2020;221:608-17.

Amphotericin‑BIDOJ
Source : Indian Dermatology Online Journal
Dr Manoj Kumar Nayak
Dr Manoj Kumar Nayak

    MBBS

    Dr Manoj Kumar Nayak has completed his M.B.B.S. from the prestigious institute Bangalore medical college and research institute, Bengaluru. He completed his M.D. Dermatology from AIIMS Rishikesh. He is actively involved in the field of dermatology with special interests in vitiligo, immunobullous disorders, psoriasis and procedural dermatology. His continued interest in academics and recent developments serves as an inspiration to work with medical dialogues.He can be contacted at editorial@medicaldialogues.in.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Journal Club Today

    8-Minute MRI Scan May Replace Painful Lumbar Puncture for Multiple Sclerosis Diagnosis: Study Suggests

    8-Minute MRI Scan May Replace Painful Lumbar Puncture for Multiple Sclerosis Diagnosis: Study...

    View All

    Health News Today

    Health Bulletin 23/May/2025

    Health Bulletin 23/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok